Patient satisfaction with televisit in chronic neurologic disorders during Covid-19 pandemic.

Background: Covid-19 pandemic has boosted telemedicine in medical clinical practice. Experience in the management of chronic neurological disorders is limited as well as patient opinion. During Covid-19 pandemic, we evaluated patients' satisfaction and opinion about televisits in a large group of patients with chronic neurological disorders.

Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?

Purpose: In the phase 2 REGOMA trial, regorafenib improved overall survival, as compared with lomustine, in glioblastoma (GBM) patients at first progression after chemoradiation. Recently, some real-life trials showed similar impact on survival but a higher rate of adverse events than in REGOMA, thus raising concerns over tolerability. The aim of this study was to assess the efficacy and tolerability of a lower intensity regorafenib regimen.

Virtual visits for chronic neurologic disorders during COVID-19 pandemic.

Background: COVID-19 pandemic has boosted telemedicine in medical clinical practice. Experiences in the management of chronic neurological disorders are limited and scattered. The aim of the study was to evaluate feasibility and efficacy of virtual visit for chronic neurological disorders during COVID-19 pandemic.

Malingering Detection of Cognitive Impairment With the b Test Is Boosted Using Machine Learning.

Here we report an investigation on the accuracy of the b Test, a measure to identify malingering of cognitive symptoms, in detecting malingerers of mild cognitive impairment. Three groups of participants, patients with Mild Neurocognitive Disorder ( = 21), healthy elders (controls, = 21), and healthy elders instructed to simulate mild cognitive disorder (malingerers, = 21) were administered two background neuropsychological tests (MMSE, FAB) as well as the b Test. Malingerers performed significantly worse on all error scores as compared to patients and controls, and performed poorly than controls, but comparably to patients, on the time score.